↓ Skip to main content

Dove Medical Press

Article Metrics

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations

Overview of attention for article published in Drug Design, Development and Therapy, October 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (58th percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
34 Mendeley
Title
Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
Published in
Drug Design, Development and Therapy, October 2016
DOI 10.2147/dddt.s85050
Pubmed ID
Authors

Dilek Keskin, Sevil Sadri, Ahmet Emre Eskazan

Abstract

Dasatinib is one of the second-generation tyrosine kinase inhibitors used in imatinib resistance and/or intolerance, as well as in the frontline setting in patients with chronic myeloid leukemia-chronic phase, and also in patients with advanced disease. It is also utilized in Philadelphia chromosome-positive acute lymphocytic leukemia. While choosing the appropriate tyrosine kinase inhibitor (ie, dasatinib) for each individual patient, comorbidities and BCR-ABL1 kinase domain mutations should always be taken into consideration, among other things. This review mainly focuses on patient selection prior to dasatinib administration in the treatment of chronic myeloid leukemia.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 34 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 18%
Student > Ph. D. Student 6 18%
Other 4 12%
Student > Postgraduate 2 6%
Student > Doctoral Student 2 6%
Other 6 18%
Unknown 8 24%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 7 21%
Medicine and Dentistry 7 21%
Pharmacology, Toxicology and Pharmaceutical Science 2 6%
Immunology and Microbiology 2 6%
Arts and Humanities 1 3%
Other 3 9%
Unknown 12 35%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2016.
All research outputs
#3,682,424
of 8,539,982 outputs
Outputs from Drug Design, Development and Therapy
#226
of 1,070 outputs
Outputs of similar age
#103,741
of 253,159 outputs
Outputs of similar age from Drug Design, Development and Therapy
#9
of 55 outputs
Altmetric has tracked 8,539,982 research outputs across all sources so far. This one has received more attention than most of these and is in the 56th percentile.
So far Altmetric has tracked 1,070 research outputs from this source. They receive a mean Attention Score of 3.8. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 253,159 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.